Phase I/II Randomized Study of a GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine With or Without a PD-1 Blockade Antibody (Nivolumab) and CD137 Agonist Antibody (Urelumab) for the Neoadjuvant and Adjuvant Treatment of Patients With Surgically Resectable Adenocarcinoma of the Pancreas
Summary
The purpose of this study is to determine whether CY/GVAX with nivolumab is more effective than CY/GVAX alone in altering the pancreatic tumor microenvironment (IL17 expression) to aid in the anti-tumor response.
General Information
NCT#: NCT02451982
Study ID: J1568
Trial Phase: Phase I/II
Trial Sponsor: Sidney Kimmel Comprehensive Cancer Center
Therapies Used in This Trial: GVAX, Cyclophosphamide, Nivolumab, Urelumab
Sign In